P/E ratio for Agenus (AGEN)
P/E ratio as of April 2024 (TTM): -8.73
According to Agenus 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.72941. At the end of 2022 the company had a P/E ratio of -2.98.
P/E ratio history for Agenus from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.98 | -83.02% |
| 2021 | -17.6 | 490.67% |
| 2020 | -2.97 | -41.21% |
| 2019 | -5.06 | 216.04% |
| 2018 | -1.60 | -38.99% |
| 2017 | -2.62 | -4.66% |
| 2016 | -2.75 | -29.01% |
| 2015 | -3.87 | -32.38% |
| 2014 | -5.73 | 154.32% |
| 2013 | -2.25 | -72.56% |
| 2012 | -8.21 | 406.22% |
| 2011 | -1.62 | -61.54% |
| 2010 | -4.22 | 168.62% |
| 2009 | -1.57 | 66.67% |
| 2008 | -0.9421 | -61.88% |
| 2007 | -2.47 | 58.27% |
| 2006 | -1.56 | -45.17% |
| 2005 | -2.85 | -63.58% |
| 2004 | -7.82 | 19.46% |
| 2003 | -6.55 | 11.39% |
| 2002 | -5.88 | -5.79% |
| 2001 | -6.24 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.5 | -220.80% | 🇺🇸 USA |
 Merck MRK | 69.7 | -898.63% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 12.3 | -240.99% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 11.7 | -233.71% | 🇬🇧 UK |
 Celldex Therapeutics CLDX | -15.4 | 76.70% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.